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Within the UK blood transfusion services, there is currently no
recommendation for the use of either clotted or anticoagulated
samples for antibody identification testing. This report describes
three cases in which the detection of IgM antibodies was impeded
by the use of anticoagulated samples. Two patient samples, referred
for compatibility testing, were both identified as having IgM
complement-activating anti-S and the remaining case involved an
antenatal patient with IgM complement-activating anti-Vel. In all
three cases, the coincidental referral and investigation of both
clotted and anticoagulated samples led to the discrepancy in serum
and plasma test results becoming apparent. Potential errors in
selection of suitable blood for transfusion and appropriate antenatal
management were avoided by correct identification of the
antibodies present using the clotted samples.
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The suitability of anticoagulated or clotted samples
for pretransfusion testing has been the object of
investigation.1 Kidd antibodies, in particular, have
received close scrutiny due to their association with
delayed hemolytic transfusion reactions, their ability to
activate complement,and the earlier reported difficulty
of their detection in systems with reduced sensitivity
to complement-activating antibodies.2 It is widely
accepted that, given the improvements in antibody
detection by the antiglobulin test (AGT) resulting from
the use of different enhancement media (e.g., LISS,
polybrene, and PEG) and the advances in AGT
technology (gel and bead techniques), the necessity to
detect complement activation by capable IgG
antibodies has been reduced and possibly eliminated.3
The general conclusion is there is no significant
difference in detection rates when using
anticoagulated or clotted samples.4
The Welsh Blood Service (WBS) laboratories
provide an antenatal antibody screening service for
seven hospitals within the region as well as a reference
service for serologic investigations for 15 hospitals.
The majority of hospital blood banks served use
automated sampling systems for RBC typing and
antibody investigations and, consequently, use
anticoagulated samples.
Subsequently, anticoagulated samples were
increasingly referred to the WBS for routine antenatal
and patient antibody investigations. Reported here are
three cases that serve to emphasize the limitations of
anticoagulated samples used by the current testing
protocol of the WBS when performing RBC antibody
investigations. In each case, the detection of an IgM
complement-activating antibody was impeded by the
use of anticoagulated samples.
Materials and Methods
Routine tests for antibody identification were
performed; they included the standard tube AGT using
1.5% LISS-suspended RBCs incubated at 37°C for 30
minutes, an agglutination test using PBS-suspended
RBCs incubated at 18°C for 60 minutes, and a two-stage
prepapainized agglutination test incubated at 37°C for
30 minutes. DiaMed column gel ID AGT cards (DiaMed
AG, Cressier sur Morat, Switzerland) were used
according to manufacturer’s instructions. Polyspecific
anti-human globulin (AHG) reagent (i.e., combination
of anti-IgG and anti-C3d) was used for both the LISS
tube test (Lorne Laboratories, Reading, UK) and
DiaMed ID cards (DiaMed AG). All tests were
performed using plasma and serum samples with
appropriate nine-cell panels.
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Variation in the pattern of reactivity obtained when
testing plasma and serum samples with the panel RBCs
by the AGT implied that the detected antibody was a
complement-dependent IgM antibody. A series of
further tests was performed to confirm the presence of
a complement-dependent IgM antibody. Treatment of
the serum samples with dithiothreitol (DTT) (Sigma-
Aldrich, Steinheim, Germany) was performed to verify
the presence of an IgM antibody. Equal volumes of 0.01
M DTT were incubated with the patient’s serum for 30
minutes at room temperature. PBS was added to the
patient’s serum in a second tube and similarly
incubated as a control. Doubling dilutions were
performed on the patient’s untreated serum, DTT-
treated serum, and PBS control serum. All dilutions
were tested using appropriate RBCs by a LISS-AGT.
Reactions were graded macroscopically; due to
variation in interpretation of reaction grades, a twofold
difference in titer result was considered to be
significant.
A two-stage EDTA test was also performed on those
anticoagulated patient samples in which a
complement-dependent antibody was suspected and
when the anticoagulated sample did not react by the
tube LISS AGT. A neutralized EDTA solution at pH 7.2
was prepared using 4.0 g of K2EDTA and 0.3 g of NaOH
in 100 mL of distilled water. EDTA solution was added
to the patient’s plasma sample at a 1 in 10 dilution with
incubation at room temperature for 10 minutes. Two
volumes of the treated plasma were subsequently
incubated with reagent panel RBCs suspended in PBS
for 60 minutes at 37°C. After incubation, the RBCs
were washed and incubated for 15 minutes with a
fresh source of complement. (The complement was
derived from a pool of group-compatible non-
transfused donor sera that tested negative for the
presence of irregular RBC antibodies and was stored
frozen within 24 hours of donation.)  After additional
washing, polyspecific AHG reagent was added and the
test was centrifuged and read.
The clinical significance of RBC IgG antibodies can
be investigated using a chemiluminescence (CL) test
based on the method described by Downing et al.5 In
the following cases, where appropriate, the CL assay
was performed to demonstrate the absence of a
clinically significant IgG antibody. Briefly, the patient’s
serum was incubated separately with antigen-positive
and antigen-negative RBCs. After washing, the
sensitized RBCs were incubated with the mononuclear
cell preparation in the presence of luminol. Monocyte
activation, as indicated by increased chemilumi-
nescence, was measured every 4 minutes for 2 hours.
The CL test results were reported as an opsonic index;
an opsonic index < 1.2 is indicative of a clinically
insignificant IgG antibody.
In each case,compatibility testing was required and
performed using serum samples tested with RBCs
antigen-negative for the previously identified antibody
by a LISS AGT.
Case Reports
Case 1
In 1991, a 50-year-old woman was admitted to a
local hospital with a Hb of 8.3 g/dL after a viral
infection. Serologic investigations revealed the
presence of anti-D and a strongly positive DAT. The
patient was diagnosed with autoimmune hemolytic
anemia. Transfusion was required on three occasions
from 1991 to 1999; the patient received a total of nine
units of RBCs. In 1999,a second antibody was detected
in the patient’s serum and samples were referred to the
WBS for antibody identification and compatibility
testing. The presence of anti-S and anti-D was
confirmed. In January 2002, the patient presented with
a Hb of 7.8 g/dL and was referred for compatibility
testing presplenectomy. Pretransfusion testing was
performed using anticoagulated samples. The anti-S
was no longer detectable by the LISS AGT; however
anti-S could be detected by a saline 18°C tube
agglutination test. Additional anticoagulated and
clotted samples were requested to further investigate
the initial findings.
The patient’s RBCs were grouped as A, D– (rr) and
were found to react in the DAT with polyspecific and
monospecific anti-C3 AHG reagents; negative reactions
were obtained when the RBCs were tested using anti-
IgG AHG. Routine antibody identification panels using
plasma revealed the presence of anti-D reactive by LISS
AGT; the anti-D was not confirmed active by papain
tests due to the presence of a nonspecific papain
autoantibody. Anti-S was detectable by saline 18°C
agglutination tube tests and in the LISS AGT before
washing. The anti-S was not detectable after washing,
addition of AHG reagent, and centrifugation. The anti-S
was also detectable when performing a DiaMed gel
card AGT. We suspected the presence of an IgM
complement-activating anti-S and we repeated our
investigations using serum samples (Table 1).
Antiglobulin test titrations were performed using
D+ ss, D– Ss, and D– rr ss LISS-suspended RBCs.
Plasma or serum for red cell serology?
Titration of the patient’s serum demonstrated the anti-
D to be detectable at a 1 in 16 dilution and anti-S at a 1
in 4 dilution. DTT treatment of the patient’s serum
destroyed anti-S activity such that no reactions were
observed in the titrations by the AGT; the anti-D
remained detectable at a dilution of 1 in 8. As
expected, no reactions were obtained with D– rr ss
RBCs (Table 2).
Further testing was performed to confirm the
characteristics of the antibody (Table 3). The anti-S was
detectable by a normal ionic strength saline (NISS)
AGT, therefore excluding the possibility that the
detection of the anti-S was a LISS phenomenon as had
been previously described with other antibody
specificities.6 The use of monospecific anti-IgG
rendered the anti-S undetectable in the LISS AGT even
with the use of a serum sample. Our results confirmed
the anti-S to be an IgM complement-activating
antibody. Failure of the patient’s RBCs to react with the
anti-S detected by saline 18°C agglutination tests
suggested the anti-S to be an alloantibody; this was
confirmed by determining the patient’s RBCs to be S–
using an in-house IgG anti-S typing reagent.
The patient was transfused with six units of group
A,D– (rr) ss RBCs units without incident;postoperative
Hb was 13.2 g/dL.
Case 2
In December 2001, a sample was received from an
antenatal patient at 11 weeks’ gestation for routine
antenatal screening. The patient had two previous
pregnancies with no record of any previous
transfusions and no irregular antibodies detected
during previous antenatal screening. Clotted and
anticoagulated samples were received for antenatal
antibody screening. Automated testing was performed
using the anticoagulated sample with bromelinized
RBCs on the Olympus PK7200 (Olympus,Tokyo, Japan)
by hemagglutination and using the clotted sample by a
solid phase antiglobulin test (SPAT) on the Tecan
Genesis RSP 150 (Tecan Schweiz AG, Männedorf,
Switzerland). The sample was identified as antibody
positive by the SPAT method on the Tecan Genesis RSP
150. The sample was then referred to the Patient
Diagnostic Services department for antibody
identification and titration as necessary.
Routine antibody identification panels using the
patient’s serum sample revealed the presence of an
antibody that reacted with all panel RBCs tested by
papain and LISS AGT with a negative autocontrol. The
patient’s serum was tested using an additional selected-
RBC panel to exclude the presence of a combination of
the more common antibody specificities and with a
panel of RBCs with the following rare phenotypes:
Kp(b–), k–, Lu(b–), Yt(a–), Co(a–), and Vel–. The
patient’s serum failed to react with the Vel– RBC. Anti-
Vel was confirmed by testing with additional examples
of Vel– RBCs. No additional RBC antibodies were
detected and the patient’s own RBCs typed as Vel–.
Due to insufficient serum, further testing by the AGT
was performed using the referred anticoagulated
sample. Before the AGT washing phase, agglutination
was observed throughout the LISS panel when using
the anticoagulated sample; however, after washing, the
anti-Vel was undetectable by LISS AGT (Table 4).
Vel antibodies are characteristically IgM
complement-activating antibodies; therefore,
predictably discrepant results were obtained when
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Table 1. Case 1: results of routine antibody identification panels
Saline Prepapainized
18°C test test LISS AGT DiaMed test
Plasma sample Anti-S PNSA* Anti-D† Anti-D and
anti-S
Serum sample Anti-S PNSA* Anti-D and Anti-D and
anti-S anti-S
*An apparently nonspecific papain autoantibody detected.
†Before AGT washing, positive reactions giving anti-S pattern were observed.
Table 3. Case 1: results of additional testing by AGT 




Serum sample Anti-D and anti-S Anti-D* Anti-D and anti-S
Plasma sample Anti-D* Anti-D* Anti-D*
*Before AGT washing, positive reactions demonstrating anti-S pattern were observed.
Table 2. Case 1: results of AGT titrations using untreated and DTT-treated
serum*
RBC Dilution
phenotype Neat 1:2 1:4 1:8 1:16 1:32
Untreated R1R1 ss 5 4 3 2 2
† 0
serum sample rr Ss 4 3 2 0 0 0
rr ss 0 0 0 0 0 0
DTT-treated R1R1 ss NA 4 3 2 2 0
serum sample rr Ss NA 0 0 0 0 0
rr ss NA 0 0 0 0 0
PBS control R1R1 ss NA 4 3 2 0 0
serum sample rr Ss NA 4 2 0 0 0
rr ss NA 0 0 0 0 0
*Reactions graded according to system described in Table 12.2 Guidelines for Blood
Transfusion Services in the United Kingdom.16
†Endpoints of titration in bold figures.
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Plasma or serum for red cell serology?
testing plasma and serum samples. The plasma sample
was further tested by a two-stage EDTA AGT. This
technique permits the detection of complement-
activating antibodies in plasma samples by the
subsequent incubation of IgM-sensitized RBCs with a
fresh source of complement. Complement
enhancement of the routine tests by a two-stage EDTA
AGT revealed the anti-Vel.
Titration of the patient’s serum demonstrated anti-
Vel detectable at a 1 in 4 dilution. DTT treatment of the
patient’s serum (as previously described) destroyed the
anti-Vel activity such that no reactions were observed
in the titrations by the AGT (Table 5).
IgM Vel antibodies are not associated with HDN.
The clinical significance of anti-Vel with respect to its
ability to cause HDN was confirmed using a CL test. CL
assay results were negative (opsonic index < 1.2).
Results of the serologic investigations confirmed the
anti-Vel as an IgM antibody; the CL test results were,
therefore, as expected.
Continuous monitoring of the antibody throughout
pregnancy was undertaken and samples from the
patient were referred on five additional occasions. On
each occasion, the antibody specificity and class were
confirmed and additional specificities were excluded.
Four units of group-compatible Vel– RBCs were kept on
standby for the mother before the expected date of
delivery. The patient delivered at 40 weeks’ gestation,
without RBC transfusion support. The cord Hb was
21.9 g/dL, bilirubin was 61 µmol/L rising to 90 µmol/L,
and the DAT was negative; all parameters indicated no
HDN.
Case 3
In November 2003, a 70-year-old man was referred
for preoperative investigations and compatibility
testing. Anticoagulated and clotted samples were
referred and initial investigations were performed on
the anticoagulated samples because the clotted
samples were inappropriately labeled. No reactions
were detected by LISS AGT using the anticoagulated
samples; however, a pattern of reactivity was detected
by a saline 18°C agglutination test. Further testing was
performed comparing the reactivity of the serum and
plasma samples.
Initial antibody investigation results using
anticoagulated samples suggested the presence of an
IgM antibody detected by the saline 18°C agglutination
test. The presence of a weak anti-S was confirmed by
tube LISS AGT using clotted samples and a DiaMed
(DiaMed AG) gel test using both anticoagulated and
clotted samples. The anti-S demonstrated typical
dosage effects and did not react with all heterozygous
Ss RBCs. Titrations using the patient’s untreated, DTT-
treated, and PBS control sera were inconclusive due to
the lack of reactivity with diluted serum. The patient’s
serum did not react with SS panel RBCs when tested by
a NISS AGT, indicating that the antibody is LISS
dependent.
The patient was successfully transfused with five
units of ABO and Rh phenotype compatible, ss RBCs
with a posttransfusion Hb of 12.2 g/dL.
Discussion
All three cases demonstrate the failings in the tube
LISS AGT to detect complement-activating IgM
antibodies when using anticoagulated samples.
Coincidental testing of plasma and serum samples
demonstrated the differences in antibody activity but it
poses the question of how many complement-
activating IgM antibodies remain undetected in plasma
samples. The clinical significance of the IgM anti-S
identified in cases 1 and 3 is unknown. S antibodies of
IgM class are rarely reported7 and both patients
reported here received S– RBCs. Anti-S can cause
immediate and delayed hemolytic transfusion reactions
and IgG anti-S has been implicated in HDN.8 It is
Table 4. Case 2: results of routine antibody identification panels 
Saline 18°C Prepapainized 
test test LISS AGT
Serum sample Anti-Vel Anti-Vel Anti-Vel
Plasma sample Not tested Not tested No antibodies
detected*
Plasma sample in Not tested Not tested Anti-Vel
2-stage EDTA test
*Before AGT washing, positive reactions were observed throughout panel.
Table 5. Case 2: results of AGT titrations using untreated and DTT-treated
serum*
RBC Dilution
phenotype Neat 1:2 1:4 1:8 1:16 1:32
Untreated Vel+ 4 3 2† 0 0 0
serum sample Vel– 0 0 0 0 0 0
DTT-treated Vel+ NA‡ 0 0 0 0 0
serum sample Vel– NA 0 0 0 0 0
PBS control Vel+ NA 3 2 0 0 0
serum sample Vel– NA 0 0 0 0 0
*Reactions graded according to system described in Table 12.2 Guidelines for Blood
Transfusion Services in the United Kingdom.16
†Endpoints of titration in bold figures.
‡Not available (addition of DTT solution produces an initial 1 in 2 dilution).
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therefore necessary that anti-S be detected during
pretransfusion testing.
Anti-Vel is rarely associated with cases of HDN; the
Vel antigen is not fully developed at birth and examples
of IgG anti-Vel are rare.9 Confirmation of the lack of
clinical significance of the anti-Vel in relation to HDN
was provided by a negative CL test result. Antenatal
screening, however, not only allows for the
identification of antibodies that may cause problems to
the fetus and neonate but also alerts the blood bank of
the presence of antibodies that may cause
pretransfusion testing problems. Anti-Vel has been
implicated in hemolytic transfusion reactions and
failure to identify this antibody could result in a
hemolytic transfusion reaction if Vel+ RBCs were
transfused.10,11 In addition, the frequency of Vel– RBCs
is 1 in 3711; failure to identify this antibody before
delivery could have resulted in significant delay in the
provision of compatible blood, if required.
The British Standards and Controls in Haematology
Guidelines for pretransfusion compatibility procedures
in blood transfusion laboratories do not advocate the
use of serum over anticoagulated samples, but they
recommend validation of any changes to the sample
used for testing.12 Serum samples, however, were
recommended for the investigation of suspected
hemolytic transfusion reactions in the annual Serious
Hazards of Transfusion report (2001–2002) in
recognition of the ability to detect weak complement-
binding antibodies in serum samples.13 Studies
investigating the suitability of samples for
pretransfusion testing conclude that there are no
significant differences in detection rates when using
either plasma or serum.14,15 There is no single
technique that will consistently outperform all other
techniques in the detection of clinically significant RBC
antibodies, but each laboratory must be aware of any
limitations of the test they perform. Because the WBS
is a reference center for RBC serology referrals, room
temperature agglutination tests are performed to assist
in the identification of cold-reactive antibodies in
complex antibody mixtures that may interfere with
LISS AGT. Failure to have performed saline 18°C
agglutination tests or to have noted the pattern of
reactions before washing could have resulted in the
antibodies in these case studies remaining undetected
in the anticoagulated samples. In each case, the use of
a clotted sample tested by both automated and manual
techniques performed at the WBS, as well as the
application of good serologic practices, facilitated the
detection of these antibodies. The standard DiaMed gel
AGT was performed in both cases where anti-S was
identified. Contrary to the results of the tube LISS AGT,
anti-S was detectable using both serum and plasma
samples by the DiaMed AGT. Although there is much
debate as to the sensitivity of the DiaMed test when
compared with the traditional LISS tube AGT, DiaMed
gel tests proved more sensitive for the detection of IgM
antibodies when using plasma samples in the cases
discussed. The washing phase in the LISS tube AGT
disrupts IgM agglutinates and, consequently, the
detection of both the anti-S and anti-Vel antibodies
using polyspecific AHG relies entirely on the activation
of complement. Lack of complement activation when
using plasma samples therefore inhibits the detection
of these antibodies by the LISS tube AGT. The omission
of a washing phase when using DiaMed AGT cards
allows IgM agglutinates to remain intact. Therefore, the
anti-S and anti-Vel antibodies were detectable in plasma
samples when using the DiaMed AGT cards despite the
lack of complement activation.
These cases are of interest because of the rare
occurrence of anti-S of IgM class and of anti-Vel. They
also serve to highlight the benefit of using clotted
samples, particularly when performing tube tests. The
WBS commenced routine antenatal screening by the
DiaMed technique using anticoagulated samples in
November 2004 and continues to use the standard tube
LISS AGT for the reference work performed. We
request the referral of clotted samples for all reference
work.
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